13 results on '"RODRIGUEZ-CENTENO, J."'
Search Results
2. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1
- Author
-
STELLA-ASCARIZ, N., MONTEJANO, R., RODRIGUEZ-CENTENO, J., ALEJOS, B., Schwimmer, Christine, BERNARDINO, J. I., RODES, B., Allavena, C., Hoffmann, C., GISSLEN, M., De Miguel, R., ESTEBAN-CANTOS, A., Wallet, Cedrick, Raffi, F., ARRIBAS, J. R., Institut de biochimie et génétique cellulaires (IBGC), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
PharmacoEpi-Drugs ,immune system diseases ,virus diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie - Abstract
Background. Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. Methods. NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression. Results. At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C. Conclusion. Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.
- Published
- 2018
3. Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
- Author
-
Alejos, B, Stella‐Ascariz, N, Montejano, R, Rodriguez‐Centeno, J, Schwimmer, C, Bernardino, JI, Rodes, B, Esser, S, Goujard, C, Sarmento‐Castro, R, De Miguel, R, Esteban‐Cantos, A, Wallet, C, Raffi, F, and Arribas, JR
- Subjects
HIV infection transmission ,ANTIRETROVIRAL agents ,AGE distribution ,CLINICAL trials ,CONFIDENCE intervals ,HIV infections ,HIV-positive persons ,MULTIVARIATE analysis ,POLYMERASE chain reaction ,REGRESSION analysis ,RNA ,STATISTICS ,TELOMERES ,WHITE people ,VIRAL load ,QUANTITATIVE research ,CROSS-sectional method ,DESCRIPTIVE statistics ,CD4 lymphocyte count - Abstract
Objectives: Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open‐label trial comparing ritonavir‐boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in antiretroviral therapy (ART)‐naïve HIV‐positive adults. Methods: A cross‐sectional study of 201 randomly selected participants who had stored samples available was carried out. We measured telomere length (i.e. the relative telomere length, calculated as the telomere to single copy gene ratio) at baseline with monochrome quantitative multiplex polymerase chain reaction (PCR). We used multivariable predictive linear regression to calculate mean differences and 95% confidence intervals (CIs) for the association between baseline telomere length and baseline characteristics. Results: The baseline characteristics of the 201 participants did not differ from those of the 805 participants in the parent trial population: 89% were male, the mean age was 39 years, 83.6% were Caucasian, 93% acquired HIV infection via sexual transmission, the mean estimated time since HIV diagnosis was 2.1 years, the mean HIV‐1 RNA load was 4.7 log10 HIV‐1 RNA copies/mL, the mean nadir and baseline CD4 counts were 301 and 324 cells/μL, respectively, and the mean CD4:CD8 ratio was 0.4. In the univariate analysis, shorter telomere length was associated with older age (per 10 years) (P < 0.001), HIV‐1 RNA ≥ 100 000 copies/mL (P = 0.001), CD4 count < 200 cells/μL (P = 0.037), lower CD4:CD8 ratio (P = 0.018), statin treatment (P = 0.004), and current alcohol consumption (P = 0.035). In the multivariable analysis, older age (P < 0.001) and HIV RNA ≥ 100 000 copies/mL (P = 0.054) were independently associated with shorter telomere length. Conclusions: Both age and HIV RNA viral load correlated with shorter blood telomere length in untreated persons living with HIV. These results suggest that HIV infection and age have synergistic and independent impacts upon immunosenescence. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Correlation between blood telomere length and CD4(+) CD8(+) T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy
- Author
-
Rodriguez-Centeno, J., Esteban-Cantos, A., Stella-Ascariz, N., Montejano, R., Miguel, R., Alejos, B., Mena-Garay, B., Rodes, B., Bernardino, J. I., Castro, J. M., Mayoral, M., Perez-Valero, I., Maria Luisa Montes, Valencia, E., Martin-Carbonero, L., Moreno, V., Cadinanos, J., Gonzalez-Garcia, J., Arnalich, F., and Arribas, J. R.
5. Clinical mutations in the TERT and TERC genes coding for telomerase components induced oxidative stress, DNA damage at telomeres and cell apoptosis besides decreased telomerase activity.
- Author
-
Fernández-Varas B, Manguan-García C, Rodriguez-Centeno J, Mendoza-Lupiáñez L, Calatayud J, Perona R, Martín-Martínez M, Gutierrez-Rodriguez M, Benítez-Buelga C, and Sastre L
- Subjects
- Humans, Apoptosis genetics, DNA metabolism, DNA Damage genetics, Mutation, Oxidative Stress genetics, RNA genetics, Telomere genetics, Telomere metabolism, Dyskeratosis Congenita genetics, Dyskeratosis Congenita metabolism, Dyskeratosis Congenita pathology, Telomerase genetics, Telomerase metabolism
- Abstract
Telomeres are nucleoprotein structures at the end of chromosomes that maintain their integrity. Mutations in genes coding for proteins involved in telomere protection and elongation produce diseases such as dyskeratosis congenita or idiopathic pulmonary fibrosis known as telomeropathies. These diseases are characterized by premature telomere shortening, increased DNA damage and oxidative stress. Genetic diagnosis of telomeropathy patients has identified mutations in the genes TERT and TERC coding for telomerase components but the functional consequences of many of these mutations still have to be experimentally demonstrated. The activity of twelve TERT and five TERC mutants, five of them identified in Spanish patients, has been analyzed. TERT and TERC mutants were expressed in VA-13 human cells that express low telomerase levels and the activity induced was analyzed. The production of reactive oxygen species, DNA oxidation and TRF2 association at telomeres, DNA damage response and cell apoptosis were determined. Most mutations presented decreased telomerase activity, as compared to wild-type TERT and TERC. In addition, the expression of several TERT and TERC mutants induced oxidative stress, DNA oxidation, DNA damage, decreased recruitment of the shelterin component TRF2 to telomeres and increased apoptosis. These observations might indicate that the increase in DNA damage and oxidative stress observed in cells from telomeropathy patients is dependent on their TERT or TERC mutations. Therefore, analysis of the effect of TERT and TERC mutations of unknown function on DNA damage and oxidative stress could be of great utility to determine the possible pathogenicity of these variants., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
6. Monocyte Activation and Ageing Biomarkers in the Development of Cardiovascular Ischaemic Events or Diabetes in People with HIV.
- Author
-
Bernardino JI, Alejos B, Rodriguez-Centeno J, Esteban-Cantos A, Mora-Rojas B, Montejano R, De Miguel R, Montero-Alonso M, Ayerdi O, Hernández-Gutierrez C, Curran A, Arribas JR, and Rodés B
- Abstract
We investigated whether blood telomere length (TL), epigenetic age acceleration (EAA), and soluble inflammatory monocyte cytokines are associated with cardiovascular events or diabetes (DM) in people living with HIV (PLHIV). This was a case-control study nested in the Spanish HIV/AIDS Cohort (CoRIS). Cases with myocardial infarction, stroke, sudden death, or diabetes after starting antiretroviral therapy were included with the available samples and controls matched for sex, age, tobacco use, pre-ART CD4 cell count, viral load, and sample time-point. TL (T/S ratio) was analysed by quantitative PCR and EAA with DNA methylation changes by next-generation sequencing using the Weidner formula. Conditional logistic regression was used to explore the association with cardiometabolic events. In total, 180 participants (94 cases (22 myocardial infarction/sudden death, 12 strokes, and 60 DM) and 94 controls) were included. Of these, 84% were male, median (IQR) age 46 years (40-56), 53% were current smokers, and 22% had CD4 count ≤ 200 cells/mm
3 and a median (IQR) log viral load of 4.52 (3.77-5.09). TL and EAA were similar in the cases and controls. There were no significant associations between TL, EAA, and monocyte cytokines with cardiometabolic events. TL and EAA were mildly negatively correlated with sCD14 (rho = -0.23; p = 0.01) and CCL2/MCP-1 (rho = -0.17; p = 0.02). We found no associations between TL, EAA, and monocyte cytokines with cardiovascular events or diabetes. Further studies are needed to elucidate the clinical value of epigenetic biomarkers and TL in PLHIV.- Published
- 2023
- Full Text
- View/download PDF
7. Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals.
- Author
-
Chalouni M, Rodriguez-Centeno J, Samri A, Blanco J, Stella-Ascariz N, Wallet C, Knobel H, Zucman D, Alejos Ferreras B, Autran B, Thiebaut R, Raffi F, and Arribas JR
- Subjects
- ADP-ribosyl Cyclase 1 immunology, Adult, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, CD4 Lymphocyte Count methods, Female, HIV Infections drug therapy, HIV Seropositivity immunology, HIV-1 drug effects, HIV-1 immunology, Humans, Immunologic Memory immunology, Immunophenotyping methods, Lymphocyte Activation immunology, Male, Middle Aged, Viral Load immunology, Anti-Retroviral Agents immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, HIV Infections immunology, T-Lymphocyte Subsets immunology, Telomere immunology
- Abstract
In 31 participants who started first-line antiretroviral therapy in the NEAT 001/ANRS 143 clinical trial, we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03). This increase was positively correlated with both the change in the percentage of CD4+ T-cells and with the decrease of CD38+ molecules on Central Memory CD8+ and negatively correlated with the change in the percentage of CD4+ Effector Memory cells. Increase in TL could be an expression of immune reconstitution and the associated decrease in immune activation. We acknowledge for the low statistical power due to the small sample size and the potential for false positive results due to multiple testing. Hence, further studies are needed to confirm these observations., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: J.R.C reports personal fees from ViiV and received payment for development of educational lectures from Gilead. J.B. is founder and CEO of AlbaJuna Therapeutics, S.L. and reports grants from MSD outside the submitted work. F.R. received research funding or honoraria from Gilead Sciences, Janssen, Merck, MSD, ViiV Healthcare. J.R.A reports advisory fees, speaker fees and grant support from Viiv, Janssen, Gilead, MSD, Teva and Alexa. Competing interests of the authors do not alter the adherence to all Plos One policies on sharing data and materials.
- Published
- 2020
- Full Text
- View/download PDF
8. Dyskerin Mutations Present in Dyskeratosis Congenita Patients Increase Oxidative Stress and DNA Damage Signalling in Dictyostelium Discoideum .
- Author
-
Rodriguez-Centeno J, Perona R, and Sastre L
- Subjects
- Amino Acid Sequence, Animals, Cell Proliferation, Cells, Cultured, Dictyostelium, Gene Expression Regulation, Gene Knock-In Techniques, Humans, Reactive Oxygen Species metabolism, Telomere, Cell Cycle Proteins genetics, DNA Damage, Dyskeratosis Congenita genetics, Dyskeratosis Congenita metabolism, Mutation, Nuclear Proteins genetics, Oxidative Stress, Signal Transduction
- Abstract
Dyskerin is a protein involved in the formation of small nucleolar and small Cajal body ribonucleoproteins. These complexes participate in RNA pseudouridylation and are also components of the telomerase complex required for telomere elongation. Dyskerin mutations cause a rare disease, X-linked dyskeratosis congenita, with no curative treatment. The social amoeba Dictyostelium discoideum contains a gene coding for a dyskerin homologous protein. In this article D. discoideum mutant strains that have mutations corresponding to mutations found in dyskeratosis congenita patients are described. The phenotype of the mutant strains has been studied and no alterations were observed in pseudouridylation activity and telomere structure. Mutant strains showed increased proliferation on liquid culture but reduced growth feeding on bacteria. The results obtained indicated the existence of increased DNA damage response and reactive oxygen species, as also reported in human Dyskeratosis congenita cells and some other disease models. These data, together with the haploid character of D. discoideum vegetative cells, that resemble the genomic structure of the human dyskerin gene, located in the X chromosome, support the conclusion that D. discoideum can be a good model system for the study of this disease.
- Published
- 2019
- Full Text
- View/download PDF
9. Structure of Dictyostelium discoideum telomeres. Analysis of possible replication mechanisms.
- Author
-
Rodriguez-Centeno J, Manguán-García C, Perona R, and Sastre L
- Subjects
- Cell Proliferation genetics, DNA, Ribosomal metabolism, Heterochromatin genetics, Heterochromatin metabolism, Homologous Recombination, Mutation, Telomerase genetics, Telomere metabolism, DNA, Ribosomal genetics, Dictyostelium physiology, Tandem Repeat Sequences genetics, Telomerase metabolism, Telomere genetics
- Abstract
Telomeres are nucleo-protein structures that protect the ends of eukaryotic chromosomes. They are not completely synthesized during DNA replication and are elongated by specific mechanisms. The structure of the telomeres and the elongation mechanism have not been determined in Dictyostelium discoideum. This organism presents extrachromosomal palindromic elements containing two copies of the rDNA, also present at the end of the chromosomes. In this article the structure of the terminal region of the rDNA is shown to consist of repetitions of the A(G)n sequence where the number of Gs is variable. These repeats extend as a 3' single stranded region. The G-rich region is preceded by four tandem repetitions of two different DNA motifs. D. discoideum telomere reverse transcriptase homologous protein (TERTHP) presented RNase-sensitive enzymatic activity and was required to maintain telomere structure since terthp-mutant strains presented reorganizations of the DNA terminal regions. These modifications were different in several terthp-mutants and changed with their prolonged culture and subcloning. However, the terthp gene is not essential for D. discoideum proliferation. Telomeres could be maintained in terthp-mutant strains by homologous recombination mechanisms such as ALT (Alternative Lengthening of Telomeres) or HAATI (heterochromatin amplification-mediated and telomerase-independent). In agreement with this hypothesis, the expression of mRNAs coding for several proteins involved in homologous recombination was induced in terthp-mutant strains. Extrachromosomal rDNA could serve as substrate in these DNA homologous recombination reactions., Competing Interests: The authors have declared that no competing interest exist.
- Published
- 2019
- Full Text
- View/download PDF
10. Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.
- Author
-
Sánchez-Conde M, Rodriguez-Centeno J, Dronda F, López JC, Jiménez Z, Berenguer J, Pérez-Elías MJ, Moreno S, Rodés B, and Brañas F
- Subjects
- Aged, Aging, Anti-Retroviral Agents therapeutic use, DNA Methylation, Female, Frailty, HIV Infections drug therapy, HIV Infections genetics, Humans, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear metabolism, Male, Middle Aged, Phenotype, Biomarkers metabolism, HIV Infections pathology
- Abstract
Aim: To evaluate the association between DNA methylation and frailty in the HIV-infected population and to investigate the usefulness of assessing frailty as a clinical marker to identify age acceleration., Methods: Frailty was assessed according to Fried's frailty phenotype. DNA methylation was analyzed in 10 frail patients, and compared with 10 robust control patients, all with HIV. Predicted age was inferred using the Weidner's formula. Age acceleration was assessed using the difference between predicted and chronological age., Results: HIV-infected frail patients had significantly higher biological predicted ages than chronological ages (mean acceleration: 10.3 years; p = 0.012)., Conclusions: We link age acceleration and frailty in an older HIV population. Frailty could be used in this population for implementing specific clinical approaches.
- Published
- 2019
- Full Text
- View/download PDF
11. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
- Author
-
Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, and Arribas JR
- Subjects
- Adult, Analysis of Variance, DNA blood, Darunavir administration & dosage, Darunavir pharmacology, Darunavir therapeutic use, Emtricitabine administration & dosage, Emtricitabine pharmacology, Emtricitabine therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, Raltegravir Potassium administration & dosage, Raltegravir Potassium pharmacology, Raltegravir Potassium therapeutic use, Randomized Controlled Trials as Topic, Ritonavir administration & dosage, Ritonavir pharmacology, Ritonavir therapeutic use, Tenofovir administration & dosage, Tenofovir pharmacology, Tenofovir therapeutic use, Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, HIV Infections blood, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections genetics, Telomere drug effects
- Abstract
Background: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown., Methods: NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression., Results: At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C., Conclusion: Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.
- Published
- 2018
- Full Text
- View/download PDF
12. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults.
- Author
-
Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-Garcia J, Rodriguez-Centeno J, Rodes B, Cantos AE, Alejos B, de Miguel R, Arnalich F, Perona R, and Arribas JR
- Subjects
- Adult, Dideoxynucleosides pharmacology, Dideoxynucleosides therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, RNA, Viral blood, Telomerase, Tenofovir pharmacology, Tenofovir therapeutic use, Viral Load, HIV Infections drug therapy, HIV Infections genetics, HIV Infections virology, Reverse Transcriptase Inhibitors pharmacology, Reverse Transcriptase Inhibitors therapeutic use, Telomere drug effects
- Abstract
Background: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown., Methods: A prospective cohort of human immunodeficiency virus (HIV)-infected participants with suppressed virological replication was recruited to compare whole-blood telomere length (measured by quantitative multiplex polymerase chain reaction analysis) in participants with current exposure to tenofovir disoproxil fumarate (TDF) to that in participants never exposed to TDF., Results: A total of 172 participants were included: 67 were in the TDF group, and 105 were in the non-TDF group (75 were receiving 2 nucleosides [of whom 69 were receiving abacavir], 25 were receiving a nucleos[t]ide reverse transcriptase inhibitor [N{t}RTI]-sparing regimen, and 5 were receiving lamivudine as the only nucleoside). After 2 years, the mean blood telomere length increased significantly in the whole cohort. The TDF group had significantly smaller gains in telomere length than the non-TDF group. In the analysis restricted to participants receiving N(t)RTIs, TDF exposure was not associated with an independent negative effect. In the non-TDF group, participants treated with 2 nucleosides also had significantly smaller gains in telomere length than those receiving N(t)RTI-sparing regimens or lamivudine as the only nucleoside., Discussion: In HIV-infected adults with prolonged virological suppression, treatment with TDF or abacavir was associated with smaller gains in blood telomere length after 2 years of follow-up.
- Published
- 2018
- Full Text
- View/download PDF
13. Biological Activity of the Alternative Promoters of the Dictyostelium discoideum Adenylyl Cyclase A Gene.
- Author
-
Rodriguez-Centeno J and Sastre L
- Subjects
- Adenylyl Cyclases genetics, Dictyostelium genetics, Protozoan Proteins genetics, Adenylyl Cyclases biosynthesis, Dictyostelium enzymology, Gene Expression Regulation, Enzymologic physiology, Promoter Regions, Genetic physiology, Protozoan Proteins biosynthesis, Transcription, Genetic physiology
- Abstract
Amoebae of the Dictyostelium discoideum species form multicellular fruiting bodies upon starvation. Cyclic adenosine monophosphate (cAMP) is used as intercellular signalling molecule in cell-aggregation, cell differentiation and morphogenesis. This molecule is synthesized by three adenylyl cyclases, one of which, ACA, is required for cell aggregation. The gene coding for ACA (acaA) is transcribed from three different promoters that are active at different developmental stages. Promoter 1 is active during cell-aggregation, promoters 2 and 3 are active in prespore and prestalk tip cells at subsequent developmental stages. The biological relevance of acaA expression from each of the promoters has been studied in this article. The acaA gene was expressed in acaA-mutant cells, that do not aggregate, under control of each of the three acaA promoters. acaA expression under promoter 1 control induced cell aggregation although subsequent development was delayed, very small fruiting bodies were formed and cell differentiation genes were expressed at very low levels. Promoter 2-driven acaA expression induced the formation of small aggregates and small fruiting bodies were formed at the same time as in wild-type strains and differentiation genes were also expressed at lower levels. Expression of acaA from promoter 3 induced aggregates and fruiting bodies formation and their size and the expression of differentiation genes were more similar to that of wild-type cells. Expression of acaA from promoters 1 and 2 in AX4 cells also produced smaller structures. In conclusion, the expression of acaA under control of the aggregation-specific Promoter 1 is able to induce cell aggregation in acaA-mutant strains. Expression from promoters 2 and 3 also recovered aggregation and development although promoter 3 induced a more complete recovery of fruiting body formation.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.